Research project

The company has established multiple precise drug research and development pipelines targeting specific targets.

BTK (full name Bruton's tyrosine kinase), also known as Bruton's tyrosine kinase, is a key kinase in the B cell receptor (BCR) signaling pathway. It is widely expressed in different types of malignant hematological diseases and participates in the proliferation, differentiation, and apoptosis of B cells. Due to the excellent specificity of BTK small molecule inhibitors, inhibiting BTK can effectively treat malignant tumors such as non Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), as well as autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, urticaria, etc. BTK inhibitors have therefore become the most promising drugs in the market for hematological malignancies and autoimmune diseases.

探索详请

TRK-ALK-ROS1 inhibitor project

The characteristic is broad-spectrum anti-cancer with three targets, strong efficacy, and high dosage. Currently, there are no similar products on the market.

Addressing the current issue of resistance to single target drugs. The indications are non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, etc. There is currently a high demand in the domestic market, and no similar products have been launched yet.

探索详请

c-MET TRK inhibitor project

Double target MET and TRK mutation gene inhibitors, indications: breast, adenocarcinoma, kidney cancer, etc. The company has now screened compound ZW405, which has high inhibitory activity against c-MET kinase. Currently, there are no similar products on the market internationally.

探索详请

PROTAC/Molecular Adhesive Project

This project is an innovative technology that combines inhibitor molecules such as TRK and KRas with PROTAC technology. Dozens of compounds, TRK-PROTACS and KRas PROTACs, have been synthesized and their activity is currently being tested. At present, there are no BTKI-PROTAC molecular drugs on the market worldwide.

探索详请

BTK inhibitor project
TRK-ALK-ROS1 inhibitor project
c-MET TRK inhibitor project
PROTAC/Molecular Adhesive Project

PRODUCT PIPELINE

Products R&D Preclinical Phase l Phase ll Phase Ill NDA: TM471-1
(Lymphoma); TM471-2
(Autoimmune Disease); ZW-610
(Three-target Inhibitors for Solid Tumors); ZW-620
(Dual-target Inhibitors for Solid Tumors); ZW-630
(PROTAC/Molecular Glue Technique)

Indications for BTK inhibitors

lymphoma

Including various subtypes of non Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL)

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Diffuse large B-cell lymphoma (DLBCL)

Follicular lymphoma (FL)

Multiple myeloma (MM)

Borderline lymphoma (MZL)

Mantle cell lymphoma (MCL)

Fahrenheit macroglobulinemia (WM)
Autoimmune system diseases

Multiple sclerosis (MS)

Primary membranous nephropathy (PMN)

Rheumatoid arthritis (RA)

Systemic lupus erythematosus (SLE)

Chronic graft-versus-host disease (cGVHD)

Urticaria (CSU), etc